DETERMINATION OF ESCITALOPRAM OXALATE IN PHARMACEUTICAL FORMULATION BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
DOI:
https://doi.org/10.7439/ijpc.v2i1.422Keywords:
Benign Breast diseases, Fibroadenoma, fibroadenosis, cystosarcoma phylloidesAbstract
A simple, precise and sensitive reverse-phase high performance liquid chromatographic (RP-HPLC) method has been developed for the quantitation of Escitalopram oxalate in pharmaceutical formulations.Downloads
Downloads
Published
2012-04-01
Issue
Section
Research Articles
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
- The author must submit Copyright form After acceptance of the article.
How to Cite
1.
DETERMINATION OF ESCITALOPRAM OXALATE IN PHARMACEUTICAL FORMULATION BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY. Int J of Pharm Chem [Internet]. 2012 Apr. 1 [cited 2025 Jun. 12];2(1):23-6. Available from: https://ssjournals.co.in/index.php/ijpc/article/view/1282
